Changing trend in reported hepatitis B incidence among Chinese residents, 2004 – 2017

Abstract

Objective To analyze the trend of reported incidence of hepatitis B (HB) in China from 2004 to 2017 to provide evidences for developing strategies on HB prevention and control. Methods From National Public Health Science Data Center, we extracted the data on HB incidence in 31 provincial-level administrative divisions (not including Chinese Taiwan, Hong Kong Special Administrative Region and Macao Special Administrative Region) reported from March 2004 through March 2017. The average annual percentage change (AAPC) in region-, gender- and age group-specific HB incidence were calculated to assess variation trend of HB incidence during the period. Results From 2004 to 2017, the average reported incidence (per 100 000 population) of HB for the 31 divisions were 70.50, 75.57, 84.82, 89.00, 88.52, 88.82, 79.46, 81.54, 80.68, 71.12, 69.05, 68.57, 68.74 and 72.61, with no significant variation in the reported incidence as a whole (AAPC = 0.2%, P > 0.05); while, the increased HB incidences were reported in 9 of the divisions, with the APPCs of 5.80% for Shanxi, 4.20% for Anhui, 1.50% for Jiangxi, 1.70% for Hubei, 11.30% for Hunan, 6.70% for Guangdong, 3.50% for Guangxi Zhuang Autonomous Region, 3.10% for Hainan, 14.50% for Tibet Autonomous Region, and 4.40% for Xinjiang Production and Construction Corps, respectively (all P 0.05). The age group-specific HB incidences (per 100 000 population) were 12.78, 17.64, 80.21, 211.00, 181.62 and 163.11 for the population aged 0 – 4, 5 – 9, 10 – 19, 20 – 39, 40 – 59, and 60 years and above, respectively; the age group-specific HB incidence decreased for the groups less than 20 years (AAPC = – 7.7%, – 13.6%, and – 11.6% for groups of 0 – 4, 5 – 9, 10 – 19 years, all P Conclusion During 2004 – 2017 in China, the reported incidence of hepatitis B was not significantly changed generally but the incidence showed an increasing trend in some regions and the residents aged 60 years and above is the key population for hepatitis B prevention.